Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219940 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
A Phase 1 study of Healthy Subjects and Targeted Therapy, sponsored by Shine-On Biomedical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07219940: Recruiting Phase 1 study of Healthy Subjects and Targeted Therapy, sponsored by Shine-On Biomedical Co..
NCT07219940 is a Phase 1 study of Healthy Subjects and Targeted Therapy that is actively recruiting participants, run by Shine-On Biomedical Co.. The registered enrollment target is 15 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219940, a Phase 1 study of Healthy Subjects and Targeted Therapy, is actively recruiting participants, sponsored by Shine-On Biomedical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Conditions Studied
Interventions
- DRUG SOB100
Study Locations (1)
Maryland
- Parexel International - Baltimore Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT07219940 shows while recruiting
NCT07219940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which SOB100 is the first listed.
NCT07219940 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07219940 about?
NCT07219940 is a clinical study titled "A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects". The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
What is the current status of trial NCT07219940?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-12-01. Estimated completion is 2027-03.
What conditions does trial NCT07219940 study?
This clinical trial studies the following conditions: Healthy Subjects, Targeted Therapy, Exosome.
What interventions are being tested in trial NCT07219940?
The interventions under investigation include: SOB100 (DRUG).
Who is sponsoring clinical trial NCT07219940?
This trial is sponsored by Shine-On Biomedical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219940 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219940's enrollment target sits among peer trials
15 61st of 69 higher than 9 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
-
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI